Initial Effectiveness of mRNA-1273 Against SARS-CoV-2 Infection and Hospitalization in Young Children
Our findings suggest that mRNA-1273 vaccine effectiveness was initially strong against symptomatic SARS-CoV-2 infection and hospitalization in children aged 6 months to 5 years. Further research is needed to understand long-term effectiveness.
Authors
- Catherine S. Birken (ORCID: https://orcid.org/0000-0003-0308-8645)
- Jonathon L. Maguire (ORCID: https://orcid.org/0000-0002-4083-8612)
- Mary Aglipay (ORCID: https://orcid.org/0009-0002-9358-895X)
- Sarah Swayze (ORCID: https://orcid.org/0009-0001-1284-9162)
- Charles D. G. Keown‐Stoneman (ORCID: https://orcid.org/0000-0001-8790-1589)
- Muhammad Mamdani (ORCID: https://orcid.org/0000-0001-5199-6344)
- Jeffrey C. Kwong (ORCID: https://orcid.org/0000-0002-7820-2046)
- Ashleigh R. Tuite (ORCID: https://orcid.org/0000-0002-4373-9337)
Institutions
- St. Michael's Hospital (CA)
- University Health Network (CA)
- 3M (United States) (US)
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- St Michael’s Hospital (IE)
- Public Health Ontario (CA)
- SickKids Foundation (CA)
- Institute for Clinical Evaluative Sciences (CA)
- St Michael's Hospital (GB)
- Unity Health Toronto
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1093/ofid/ofae718
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Bayer
- OPEC Fund for International Development
- Boehringer Ingelheim
- University of Toronto
- International Council for the Exploration of the Sea
- Bristol-Myers Squibb Canada
- Canadian Institutes of Health Research
- Department of Family and Community Medicine, University of Toronto